PTGX Stock Chart & Fundamental Analysis

Fundamentals Charts

About PROTAGONIST THERAPEUTICS INC

Name

PROTAGONIST THERAPEUTICS INC

CEO

Dinesh V. Patel

Website

www.protagonist-inc.com

Industry

Healthcare

Year Founded

2006

Employees

132

Protagonist Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on discovering and advancing peptide-based therapies for blood, inflammatory, and immune-mediated disorders. The company develops clinical candidates across hematological and broader blood conditions as well as inflammatory disease, and generated $46.0 million of revenue in FY2025.

Analyst Ratings

Consensus Recommendation

Buy6

Hold1

Sell1

Fundamentals & Financials

Revenue (TTM)

$281.9M

Net Income (TTM)

$82.9M

EPS (TTM)

$1.22

ROA (TTM)

9.36%

Current Ratio

21.71

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q2 FY2026	Q1 FY2026	Q4 FY2025
Revenue	$213,475K	$56,368K	$7,437K
Cost of Sales	$0	$407,000	$0
Gross Profit	$213,475K	$55,961K	$7,437K
Operating Income	$158,766K	-$3,648K	-$50,355K
Net Income	$162,849K	$3,783K	-$44,384K
EPS	$2.47	$0.058	-$0.69

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

PROTAGONIST THERAPEUTICS INC's Technical Indicators Summary

PTGX exhibits characteristics of a strong uptrend, with price well above short-, medium- and long-term moving averages and ADX confirming a firm trend. Momentum measures and MACD show pronounced bullish momentum even as some oscillators register overbought readings, and on-balance volume supports the advance. Bollinger band placement hints at stretched levels but the classic pivot sits below price as nearby support. Volatility is moderate, suggesting trend continuation without extreme noise. Technical takeaway: Strong Buy — sustained momentum, broad moving-average support, and constructive volume underpin the bullish view.

Buy

6 signals

Neutral

1 signal

Sell

1 signal

Overall: Bullish75% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	68.64	Neutral	RSI (68.64) is neutral.
Stochastic %K (14, 3, 3)	91.55	Sell	Stochastic (91.55) > 80, indicating overbought.
CCI (20)	176.13	—	CCI (176.13) > 100, indicating strong upward momentum.
WPR (14)	-0.82	—	Williams %R (-0.82) > -20, indicating overbought.
Momentum (10)	19.52	—	Momentum (19.52) is positive.
MFI	66.20	—	MFI (66.20) is neutral.
MACD Level (12, 26)	5.85	Buy	Confirmed uptrend: MACD (5.85) is positive and above its signal line (4.95).
Bollinger Bands	$126.81 - $151.33	—	Price ($152.52) is above the upper band ($151.33).
ATR (14)	$5.63 (3.69%)	—	Moderate Volatility (3.69%).
ADX (14)	38.76	—	Strong uptrend (ADX > 25) with bullish directional movement. ADX(38.76), +DI(28.91), -DI(8.60)
OBV	23,424,157	—	Bullish volume pressure: OBV is above its 20-day SMA. OBV(23,424,157), 20D-SMA-OBV(22,806,761)
Classic Pivot Point	$149.18	—	Price ($152.52) has broken above resistance R1 ($150.99) — bullish breakout potential.
Fibonacci Pivot Point	$149.18	—	Price ($152.52) has broken above resistance R1 ($150.90) — bullish breakout potential.
Simple Moving Averages	$100.01 - $142.36(5 indicators)	—	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$101.62 - $144.22(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

A clear upside advance of 2.44% lifts PTGX over yesterday's close (148.29). With the sector roughly unchanged (0.25%), broader headwinds or tailwinds are limited. PTGX surges on FDA approval of ICOTYDE, a potential catalyst for commercial rollout.

Trading Volume

Below 10d avg (478.8K)

157.6K

vs S&P 500 Today

Outperforming Market

+2.19%

52-Week Position

Near highs

99.2%

Updated: August 12, 2026 at 17:13 UTC